DRRX
Undervalued by 3.8% based on the discounted cash flow analysis.
Market cap | $37.29 Million |
---|---|
Enterprise Value | $17.00 Million |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.48 |
Beta | 1.64 |
Outstanding Shares | 29,828,891 |
Avg 30 Day Volume | 170,462 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.02 |
---|---|
PEG | -4.62 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 1.85 |
Enterprise Value to EBIT | -0.4 |
Enterprise Value to Net Income | -1 |
Total Debt to Enterprise | 1.1 |
Debt to Equity | 1.3 |
No data
No data
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. ...